These Are the Top 10 Pharma Underperform Calls

As an investor, it doesn't pay to follow the crowd.

In this series, though, we highlight a possible exception -- the collective wisdom of our CAPS community. Read the next section if you're unfamiliar with our methodology. Skip it if you want to go straight to the results.

Why this crowd is different
Jumping into a stock because your rich neighbor did, or because you heard about it from your friend's uncle who used to work on Wall Street, or because CNBC has been talking about it nonstop is a recipe for disaster.

If there's one thing I've learned as a stock analyst, it's that any stock can be gussied up to sound like a world-beater. If there's a second thing I've learned, it's that being a smart person doesn't make you a good investor.

In the hands of a smart person with good communication skills, the never-were and never-will-be stocks sound like tickets to instant fortune. The ancient Greek philosophers made the distinction between rhetoric and knowledge. The former is convincing; the latter is true.

That's why we factor in track record in our Motley Fool CAPS community. We invite everyone to give stocks an outperform (akin to a "buy" call) or underperform rating (akin to a "sell" call) in CAPS. We then use those opinions to calculate a rating for each stock -- from one to five stars (five being the best). But -- and this is a big distinction -- we give more weight to the opinions of folks whose picks have performed well in the past.

The top 10 pharma underperform calls
So, with that methodology as prelude, I present to you the 10 one- and two-star pharma stocks with the most CAPS community member underperform ratings (I used a minimum market capitalization of $100 million). Remember, stocks are rated on a five-star scale by our CAPS community, so one- and two-star stocks are consensus underperforms.

Company Name

 Market Cap (in millions)

52-Week Price Change %

Price to Earnings (TTM)

CAPS Rating (out of 5)

Underperform Picks

Dendreon (Nasdaq: DNDN  )

     $5,215

52%

NM

**

290

Human Genome Sciences (Nasdaq: HGSI  )

     $5,090

37%

NM

*

205

USANA Health Sciences (Nasdaq: USNA  )

      $612

27%

16.1

*

198

Targacept (Nasdaq: TRGT  )

      $544

32%

NM

*

194

Herbalife (NYSE: HLF  )

     $3,234

78%

13.9

*

129

Pharmacyclics (Nasdaq: PCYC  )

      $333

410%

NM

*

117

Vanda Pharmaceuticals (Nasdaq: VNDA  )

      $174

(56%)

NM

*

117

MannKind

      $649

(28%)

NM

**

111

Acorda Therapeutics

     $1,122

27%

NM

*

99

Nature's Sunshine Products

      $132

0%

11.8

*

87

Source: Motley Fool CAPS. NM= not meaningful.

The first thing you may have noticed in the table above is the slew of NMs. In other words, these companies don't have P/E ratios because they have negative earnings. Because of the drug development process, that's not necessarily as damning in the world of pharma as it is in other industries. Still, the CAPS community isn't impressed with these 10.

More CAPS members think cancer biotech Dendreon is an underperform than any other pharma stock. Do you think it deserves this lack of love? Make your thoughts known in CAPS by clicking here. Or just go there to do further research on one of these popular stocks.

You can see the flip side -- the seven top-rated pharma stocks by clicking here.

Anand Chokkavelu doesn't own shares of any company mentioned. The Fool has a disclosure policy.


Read/Post Comments (3) | Recommend This Article (14)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On August 26, 2010, at 3:06 PM, kampaa wrote:

    I recommend $VNDA http://soc.li/ksTkScT EV/Rev ratio and trading below cash value adds up to a potential acquisition target

  • Report this Comment On August 27, 2010, at 1:07 PM, smirnovm wrote:

    May be I am not right type of the Fool, but seems most of these low caps rating stocks are doing much better than those 7 high caps ones from previous post.

  • Report this Comment On September 03, 2010, at 11:18 PM, naughtyguy wrote:

    PCYC would be my top short recommendation. Since I don't short stocks I rated this an underperform on th fool.

    I own AEZS. I predict that the price of AEZS will be twice that of PCYC a year from now (9-03-11). They both are developing cancer stocks. One way over bought and the other way oversold.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1282056, ~/Articles/ArticleHandler.aspx, 11/24/2014 1:54:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 17,810.06 91.06 0.51%
S&P 500 2,063.50 10.75 0.52%
NASD 4,712.97 11.10 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/21/2014 4:01 PM
DNDNQ $0.15 Down -0.01 -5.70%
Dendreon Corp CAPS Rating: **
HGSI.DL $0.00 Down +0.00 +0.00%
Human Genome Scien… CAPS Rating: **
HLF $40.85 Up +0.91 +2.28%
Herbalife CAPS Rating: *
PCYC $140.33 Up +1.81 +1.31%
PHARMACYCLICS, INC… CAPS Rating: **
TRGT $2.42 Down -0.04 -1.63%
Targacept , Inc. CAPS Rating: ***
USNA $107.72 Up +0.47 +0.44%
USANA Health Scien… CAPS Rating: *
VNDA $12.58 Up +0.59 +4.92%
Vanda Pharmaceutic… CAPS Rating: *

Advertisement